Stada Ranibizumab Deal Doesn’t Change Coherus’ Aspirations
Coherus Looking To Refile By End Of Year
With one foot already in oncology, biosimilars player Coherus is looking to make a splash in ophthalmology with ambitions to launch rivals to Lucentis and Eylea, as well as Avastin, in the US in the coming years. The US-based firm has acknowledged the competition it faces for biosimilars to Lucentis as Bausch Health picked up rights to Stada and Xbrane’s candidate earlier this month.
